Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
Silence Therapeutics (Nasdaq: SLN), a global clinical-stage company focused on developing siRNA therapies, has scheduled its fourth quarter and full year 2024 financial results release for February 27, 2025. The company will host a conference call and webcast at 8:00 a.m. ET / 1:00 p.m. GMT on the same day, where management will discuss financial results and provide a business update. The webcast will be accessible through the Investors section of Silence's website and will remain archived for future reference.
Silence Therapeutics (Nasdaq: SLN), un'azienda globale in fase clinica focalizzata sullo sviluppo di terapie siRNA, ha programmato il rilascio dei risultati finanziari del quarto trimestre e dell'anno intero 2024 per il 27 febbraio 2025. L'azienda ospiterà una conferenza telefonica e una diretta streaming alle 8:00 a.m. ET / 1:00 p.m. GMT lo stesso giorno, durante la quale il management discuterà i risultati finanziari e fornirà un aggiornamento sull'attività. La diretta sarà accessibile attraverso la sezione Investitori del sito web di Silence e rimarrà archiviata per future consultazioni.
Silence Therapeutics (Nasdaq: SLN), una empresa global en etapa clínica centrada en el desarrollo de terapias de siRNA, ha programado la publicación de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 27 de febrero de 2025. La empresa llevará a cabo una conferencia telefónica y una transmisión web a las 8:00 a.m. ET / 1:00 p.m. GMT el mismo día, donde la dirección discutirá los resultados financieros y proporcionará una actualización comercial. La transmisión estará disponible a través de la sección de Inversores en el sitio web de Silence y permanecerá archivada para referencia futura.
Silence Therapeutics (Nasdaq: SLN)는 siRNA 치료제 개발에 집중하는 글로벌 임상 단계 회사로, 2024년 4분기 및 연간 재무 결과 발표를 2025년 2월 27일로 예정하고 있습니다. 회사는 같은 날 오전 8시(ET) / 오후 1시(GMT)에 재무 결과를 논의하고 사업 업데이트를 제공하는 컨퍼런스 콜 및 웹캐스트를 개최할 예정입니다. 웹캐스트는 Silence의 웹사이트 투자자 섹션을 통해 접근 가능하며, 향후 참조를 위해 아카이브로 남아 있을 것입니다.
Silence Therapeutics (Nasdaq: SLN), une entreprise mondiale en phase clinique axée sur le développement de thérapies par siRNA, a programmé la publication de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour le 27 février 2025. L'entreprise animera une conférence téléphonique et un webinaire le même jour à 8h00 (ET) / 13h00 (GMT), où la direction discutera des résultats financiers et fournira une mise à jour sur les affaires. Le webinaire sera accessible via la section Investisseurs du site Web de Silence et restera archivé pour référence future.
Silence Therapeutics (Nasdaq: SLN), ein globales Unternehmen in der klinischen Phase, das sich auf die Entwicklung von siRNA-Therapien konzentriert, hat die Veröffentlichung seiner finanziellen Ergebnisse für das vierte Quartal und das Gesamtjahr 2024 auf den 27. Februar 2025 terminiert. Das Unternehmen wird am selben Tag um 8:00 Uhr ET / 13:00 Uhr GMT eine Telefonkonferenz und ein Webcast veranstalten, in dem das Management die finanziellen Ergebnisse besprechen und ein Update zum Geschäft geben wird. Der Webcast wird über den Bereich Investoren auf der Website von Silence zugänglich sein und bleibt für zukünftige Referenz archiviert.
- None.
- None.
Management will host a conference call at 8:00 a.m. ET / 1:00 p.m. GMT that day to discuss the Company’s financial results and provide a general business update. The conference call will be webcast live and available on the Investors section of the Silence website at www.silence-therapeutics.com. The webcast will also be archived on the Company’s website.
Details of the webcast and conference call:
Webcast link: https://edge.media-server.com/mmc/p/73gzxc8m
Conference call registration link: https://register.vevent.com/register/BIbb8ec3d3557e47e3a4db7b8c03339124
About Silence Therapeutics
Silence Therapeutics is a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. For more information, please visit https://www.silence-therapeutics.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213336305/en/
Inquiries:
Silence Therapeutics plc
Gem Hopkins, VP, Head of IR and Corporate Communications
ir@silence-therapeutics.com
Tel: +1 (646) 637-3208
Source: Silence Therapeutics plc
FAQ
When will Silence Therapeutics (SLN) release its Q4 and FY 2024 earnings?
What time is Silence Therapeutics (SLN) Q4 2024 earnings call?
How can investors access Silence Therapeutics (SLN) Q4 2024 earnings webcast?
Will Silence Therapeutics (SLN) Q4 2024 earnings call be archived?
